Blue Light Cystoscopy with Cysview® May Detect Certain Bladder Cancer Tumors More than Use of Standard Diagnostic Technology
In its ongoing commitment to the detection and treatment of cancer, Summerlin Hospital now offers Blue Light Cystoscopy with Cysview®, an optical imaging agent for the detection of papillary cancer of the bladder in patients with known or suspected bladder cancer. Cysview is the only FDA-approved imaging agent for use with blue-light cystoscopy.
According to the American Cancer Society, about 81,190 new cases of bladder cancer will be diagnosed in 2018, including an estimated 770 cases in Nevada. It is the fourth most common cancer in men, and occurs mainly in adults over age 55.
“Some high grade, aggressive bladder tumors can be difficult to detect with conventional white light cystoscopy,” said urologist Michael Verni, MD. “Timely detection and treatment of these tumors can improve cancer specific survival. Blue Light Cystoscopy with Cysview offers improved detection of potentially deadly bladder tumors compared to the white light cystoscopy.”
White light cystoscopy had been has been the gold standard for visualizing suspicious lesions during transurethral resection of bladder tumor (TURBT).
In Blue-Light Cystoscopy with Cysview,® the imaging solution (Cysview) is delivered into the bladder about an hour prior to the cystoscopy and is absorbed by cancerous tissue. After first using white light, the doctor then switches to blue light mode. Because of the imaging solution, other tumors that may be present become more visible, glowing bright pink under the blue light. This makes it easier for the urologist to identify and remove tumors.
Teri Koehler, bladder cancer survivor and co-founder of the Bladder Cancer Support Group that meets at Summerlin Hospital, knows firsthand how the Blue-Light Cystoscopy can benefit people. “Because of the Blue-Light, my urologist found two bladder tumors that weren’t visible under the white light, as well as one pre-cancerous tumor,” said Koehler. “The procedure itself is simple and by detecting tumors much earlier, it gives me peace of mind knowing this new technology is available.”
“Investing in technology like the Blue-Light Cystoscopy is an investment in our community’s health,” said Rob Freymuller, CEO of Summerlin Hospital. “We see this as another opportunity to improve the detection, diagnosis and treatment of cancer in Southern Nevada, and to improve our patients’ quality of life.”
About Summerlin Hospital
Summerlin Hospital is a member of The Valley Health System, a network of six acute care hospitals that provide care for patients throughout Southern Nevada and nearby communities. Located in the master-planned community of Summerlin, the 485-bed hospital offers emergency care, advanced cardiovascular care, women’s health, comprehensive maternity services, a level III neonatal intensive care unit, a children’s medical center, oncology care for adults and children, and specialty programs in stroke, chest pain, acute inpatient rehabilitation, advanced wound care and hyperbaric medicine, cardiac rehabilitation, and outpatient therapy services for adults and children.
About Cysview® (hexaminolevulinate hydrochloride) for Intravesical Solution
Cysview is indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system to perform cystoscopy with the blue light setting (Mode 2) as an adjunct to the white light setting (Mode 1). Cysview is not for repetitive use and is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.
